"Outcomes of Surgical Removal of Foreign Body Granulomas"
1 other identifier
observational
35
1 country
1
Brief Summary
Illicit subcutaneous injection of high-viscosity fluids for restoration and improvement of body contour is a growing trend all around the world. Many local and systemic complications have been described. Local complications include deformity at the site of injection, granulomas and several skin changes like erythema, induration, and plaques (well-circumscribed, elevated, superficial, solid lesion). The investigator designed a single-center, cross-sectional, retrospective, consecutive case series study and evaluated 49 surgeries performed in 35 patients with the history of foreign substances injection for cosmetic purposes and developed local complications. Investigators divided 4 groups accordingly to localization of foreign substances (FS). Group 1) FS disseminated to both lower extremities and buttocks; group 2) FS isolated to buttocks with moderate to severe skin changes, Group 3) FS isolated to lower legs with mild skin changes and superficial ulcerations and 4) FS isolated to lower legs with moderate to severe skin changes and/or ulceration. The investigators treated all patients surgically, which consisted of isolate ultrasonic liposuction for extraction of the material from the affected region (group 1) In-bloc excision and primary closure (group 2), Resection plus Vacuum assisted closure (VAC) and split thickness skin graft (STSG) (group 3) and In-bloc excision and microsurgical reconstruction (group 4). Statistical analysis was performed to find relations between type of surgery with complications, reactivation of symptoms, time for reactivation and a disease-free survival test (kaplan meier) was done.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2014
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
November 30, 2020
CompletedFirst Submitted
Initial submission to the registry
December 4, 2020
CompletedFirst Posted
Study publicly available on registry
December 10, 2020
CompletedDecember 11, 2020
December 1, 2020
6.8 years
December 4, 2020
December 9, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Complications
Describe if patients have or not postoperative complications
30 days
Secondary Outcomes (2)
Reactivation of symptoms
9 to 76 months
Time for reactivation of symptoms
9 to 76 months
Study Arms (4)
1
Foreign Substance disseminated to both lower extremities and buttocks
2
Foreign Substance isolated to buttocks with moderate to severe skin changes
3
Foreign substance isolated to lower legs with mild skin changes and superficial ulcerations
4
Foreign substance isolated to lower legs with moderate to severe skin changes and/or ulceration
Interventions
(group 1) In-bloc excision and primary closure (group 2), Resection plus Vacuum assisted closure (VAC) and split thickness skin graft (STSG) (group 3) and In-bloc excision and microsurgical reconstruction (group 4).
Eligibility Criteria
patients previously injected with foreign substances (FS) such as polymers for cosmetic soft tissue augmentation and the diagnosis of ASIA presented with mild to severe skin changes and treated surgically from January 2014 to March 2020 all in a private practice setting (Hospital Angeles Pedregal, Mexico city, MEXICO) and treated all by plastic surgeon senior author (JLM)
You may qualify if:
- History of injection of foreign substances for cosmetic purposes
- Develop symptoms of Autoimmune syndrome induced by adjuvants
- Mild to severe skin changes
You may not qualify if:
- Refuse to participate in the analysis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hospital Angeles Pedregal
Mexico City, Mexico City, 01330, Mexico
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal investigator, Plastic and reconstructive surgeon staff, MBA, FACS
Study Record Dates
First Submitted
December 4, 2020
First Posted
December 10, 2020
Study Start
January 1, 2014
Primary Completion
November 1, 2020
Study Completion
November 30, 2020
Last Updated
December 11, 2020
Record last verified: 2020-12